Transgene provides an update on its clinical and financial progress

Transgene has published results for its candidate TG4050, confirming 100% recurrence-free survival after three years in head and neck cancer. These results, from the Phase 1/2 study, highlight the potential of the myvac® platform in personalized cancer therapies.

The company has also launched a Phase 1 trial for TG4070, in combination with nivolumab, targeting non-small cell lung cancer. This development is part of a strategy to expand therapies against early-stage solid tumors.

Financially, operating income for the first nine months of 2026 amounted to €4.3 million, with cash and cash equivalents of €84.3 million at the end of September. Transgene anticipates secure financing until the beginning of 2028.